Skip to main content


Log in

Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript


Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–5551

    Article  CAS  PubMed  Google Scholar 

  2. Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665–685

    Article  CAS  PubMed  Google Scholar 

  3. Yardley DA (2008) Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 8:487–492

    Article  CAS  PubMed  Google Scholar 

  4. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC (2009) Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272–277

    Article  CAS  PubMed  Google Scholar 

  5. Goel S, Abdi E, Lewis CR, Links M, Begbie S, Clingan P, Ganju V, Beith J (2009) Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer. Asia Pac J Clin Oncol 5:32–38

    Article  Google Scholar 

  6. Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269:7–17

    Article  CAS  PubMed  Google Scholar 

  7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202

    Article  CAS  PubMed  Google Scholar 

  8. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51

    Article  CAS  PubMed  Google Scholar 

  9. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541–5552

    Article  CAS  PubMed  Google Scholar 

  10. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84–90

    Article  CAS  PubMed  Google Scholar 

  11. Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15:3970–3977

    Article  CAS  PubMed  Google Scholar 

  12. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14:7138–7142

    Article  CAS  PubMed  Google Scholar 

  13. Carraway HE, Gore SD (2007) Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol 25:1955–1956

    Article  PubMed  Google Scholar 

  14. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ (2008) Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99:689–694

    Article  CAS  PubMed  Google Scholar 

  15. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11:6382–6389

    Article  CAS  PubMed  Google Scholar 

  16. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971–984

    CAS  PubMed  Google Scholar 

  17. Kim TM, Jeong HJ, Seo MY, Kim SC, Cho G, Park CH, Kim TS, Park KH, Chung HC, Rha SY (2005) Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Clin Cancer Res 11:79–86

    CAS  PubMed  Google Scholar 

  18. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC (2006) Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16:429–438

    Article  CAS  PubMed  Google Scholar 

  19. Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Noh SH, Chung HC (2009) G-T haplotype (2677G > T/A and 3435C > T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Lett 277:155–163

    Article  CAS  PubMed  Google Scholar 

  20. Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, Kwon HJ (2007) Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 356:233–238

    Article  CAS  PubMed  Google Scholar 

  21. Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, Noh SH, Rha SY (2009) In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics 93:52–61

    Article  CAS  PubMed  Google Scholar 

  22. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

    Article  CAS  PubMed  Google Scholar 

  23. Schrump DS (2009) Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 15:3947–3957

    Article  CAS  PubMed  Google Scholar 

  24. Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H, Kudoh S (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7:1923–1930

    Article  CAS  PubMed  Google Scholar 

  25. Dejligbjerg M, Grauslund M, Christensen IJ, Tjornelund J, Buhl Jensen P, Sehested M (2008) Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark 4:101–109

    CAS  PubMed  Google Scholar 

  26. Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S (2005) Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69:603–616

    Article  CAS  PubMed  Google Scholar 

  27. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, Efimova T (2009) p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 69:4648–4655

    Article  CAS  PubMed  Google Scholar 

  28. Li-Sher FT, Ooi A, Huang D, Wong JC, Qian CN, Chao C, Ooi L, Tan YM, Chung A, Cheow PC, Zhang Z, Petillo D, Yang XJ, Teh BT (2009) p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer (in press)

  29. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, Greco A (2008) Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 88:474–481

    Article  CAS  PubMed  Google Scholar 

  30. Wang Y, Liu D, Chen P, Koeffler HP, Tong X, Xie D (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 68:1136–1143

    Article  CAS  PubMed  Google Scholar 

  31. Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P (2008) Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134:365–372

    Article  CAS  PubMed  Google Scholar 

  32. Ujházy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E (1996) Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. Int J Cancer 68:493–500

    Article  PubMed  Google Scholar 

  33. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500–4510

    Article  CAS  PubMed  Google Scholar 

Download references


This work was supported by the Korea Science and Engineering Foundation (KOSEF) Grant funded by the Korea government (MOST) (R11-2000-082-03002-0 and R11-2000-082-02008-0).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Hyun Cheol Chung.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, H., Jeung, HC., Jung, J.J. et al. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat 125, 55–63 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: